"Disease Progression" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Descriptor ID |
D018450
|
MeSH Number(s) |
C23.550.291.656
|
Concept/Terms |
Disease Progression- Disease Progression
- Disease Progressions
- Progression, Disease
- Progressions, Disease
|
Below are MeSH descriptors whose meaning is more general than "Disease Progression".
Below are MeSH descriptors whose meaning is more specific than "Disease Progression".
This graph shows the total number of publications written about "Disease Progression" by people in this website by year, and whether "Disease Progression" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 0 | 5 | 5 |
1996 | 0 | 11 | 11 |
1997 | 0 | 7 | 7 |
1998 | 0 | 12 | 12 |
1999 | 0 | 7 | 7 |
2000 | 0 | 20 | 20 |
2001 | 0 | 17 | 17 |
2002 | 0 | 25 | 25 |
2003 | 0 | 24 | 24 |
2004 | 0 | 41 | 41 |
2005 | 0 | 38 | 38 |
2006 | 0 | 53 | 53 |
2007 | 1 | 39 | 40 |
2008 | 0 | 45 | 45 |
2009 | 3 | 55 | 58 |
2010 | 3 | 52 | 55 |
2011 | 3 | 51 | 54 |
2012 | 2 | 60 | 62 |
2013 | 2 | 51 | 53 |
2014 | 4 | 56 | 60 |
2015 | 5 | 60 | 65 |
2016 | 3 | 52 | 55 |
2017 | 7 | 58 | 65 |
2018 | 9 | 67 | 76 |
2019 | 4 | 61 | 65 |
2020 | 4 | 52 | 56 |
2021 | 5 | 36 | 41 |
2022 | 0 | 23 | 23 |
2023 | 0 | 32 | 32 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Disease Progression" by people in Profiles.
-
Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and non-hospitalized individuals. Front Immunol. 2024; 15:1348041.
-
Researching COVID to enhance recovery (RECOVER) tissue pathology study protocol: Rationale, objectives, and design. PLoS One. 2024; 19(1):e0285645.
-
Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx. BMJ Open Respir Res. 2023 12 26; 10(1).
-
Advances in Imaging Techniques for Geographic Atrophy. Ophthalmic Surg Lasers Imaging Retina. 2023 Dec; 54(12):682-685.
-
Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of mental health symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM R. 2023 Dec; 15(12):1588-1604.
-
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 12 01; 34(12):2025-2038.
-
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis. Chest. 2024 Mar; 165(3):621-631.
-
Machine learning identification of patient clusters for cutaneous melanoma. Ital J Dermatol Venerol. 2023 Oct; 158(5):388-394.
-
Extracellular matrix contribution to disease progression and dysfunction in myopathy. Am J Physiol Cell Physiol. 2023 Nov 01; 325(5):C1244-C1251.
-
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 09; 24(9):989-1001.